Gary Pace

Dr. Pace is a seasoned biopharmaceutical executive with over 40 years of experience in the industry. He has held senior positions in global product development in major biotech and MedTech companies and has also co-founded several early-stage life science companies, where he moved products from the laboratory to commercialization. He is an elected Fellow of the Australian Academy of Technological Sciences and Engineering, as well as author and co-author of over 70 research papers, reviews, and patents.

Currently, Dr. Pace is also a Director of Pacira Pharmaceuticals (NASDAQ: PCRX), Simavita Ltd (ASX: SVA), Antisense Therapeutics (ASX: ANP), and Invitrocue (ASX: IVQ), and several private companies. In 2003, Dr. Pace was awarded a Centenary Medal by the Australian Government for service to Australian society in research and development. Dr. Pace holds a Ph.D. from MIT, where he was a Fulbright Scholar.